| 08:00 | Welcome and Opening remarks (3 musketeers) | Em breve |
| 08:15 | Session 1 - Welcome back!The centimeter mark or the intrathyroidal tumor. What’s the new cornerstone to define low-risk tumors? | Em breve |
| 09:00 | When size matters? Let the USG image speak! | Em breve |
| 09:30 | Debate: Molecular Makers - Ricardo Gama X US and FBNAB as decision tools | Em breve |
| 10:30 | Break | Em breve |
| 10:50 | Session 2 - The less aggressive approach to Low riskAny treatment necessary? How much treatment is enough? | Em breve |
| 11:10 | Isthmus carcinomas. Are we facing 'the ugly' low-risk PTC? | Em breve |
| 11:30 | Is a positive central lymph node (still) an indication for total thyroidectomy? | Em breve |
| 11:50 | Defining the new thyroglobulin levels | Em breve |
| 12:10 | Q & A | Em breve |
| 12:15 | The Great Debate: Who Really Needs Surgery? Thermal Ablation x Surgery (Lunch Session) | Em breve |
| 14:00 | Session 3 - Who's afraid of Partial Thyroidectomy?Keynote - Micro MTC and Lobectomy | Em breve |
| 14:20 | Lobectomy in 'aggressive' variants of papillary carcinoma | Em breve |
| 14:40 | Lobectomy in follicular carcinoma | Em breve |
| 15:00 | When things go wrong - Who needs a total thyroidectomy | Em breve |
| 15:20 | Q & A | Em breve |
| 15:30 | Coffee Break | Em breve |
| 15:50 | How Artificial Intelligence is Changing Thyroid Nodule Diagnostics | Em breve |
| 16:20 | Bread and butter for Thy Ca follow-upCurrent Definitions for response to treatment | Em breve |
| 16:40 | DTC Follow-up Strategy. What Really Matters in Lobectomy? | Em breve |
| 17:00 | What is the ideal TSH level after lobectomy? Why do we continue to use the same levels as before (used for TT)? | Em breve |